Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Aviptadil→

Aviptadil Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
40077-57-4
Molecular formula
C147H237N43O43S
Molecular weight
3326.8 g/mol
Drug class
Vasoactive intestinal peptide (VIP) analoguepeptide VPAC-receptor agonist
Mechanism of action
A synthetic analogue of vasoactive intestinal peptide that activates VIP receptors, including VPAC1, and can promote smooth-muscle relaxation and vasoactive signalling.
Indications / reported uses
  • Used in combination with phentolamine in locally authorised intracavernosal products for erectile dysfunction; the combination and route are product-specific.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/aviptadil · https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10891

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Aviptadil Environmental Risk Assessment (ERA) (the Aviptadil ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.